Dual Src and EGFR Inhibition in Combination with Gemcitabine in Advanced Pancreatic Cancer: Phase I Results

Pancreatic adenocarcinoma remains a major therapeutic challenge, as the poor (<8%) 5-year survival rate has not improved over the last three decades. Our previous preclinical data showed cooperative attenuation of pancreatic tumor growth when dasatinib (Src inhibitor) was added to erlotinib (EGFR...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Invest New Drugs
Huvudupphovsmän: Cardin, Dana B., Goff, Laura W., Chan, Emily, Whisenant, Jennifer G., Ayers, G. Dan, Takebe, Naoko, Arlinghaus, Lori R., Yankeelov, Thomas E., Berlin, Jordan, Merchant, Nipun
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2017
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891394/
https://ncbi.nlm.nih.gov/pubmed/28990119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0519-z
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk